Loading...
•
Mar 31
Absci Q1 2025 Earnings Report
Absci reported a wider net loss and higher R&D expenses while launching its first clinical trial.
Key Takeaways
Absci reported Q1 2025 revenue of $1.2M with a net loss of $26.3M, driven by increased R&D investments. The company began dosing in its ABS-101 clinical trial and strengthened its pipeline momentum.
Revenue rose to $1.2M, up from $0.9M in Q1 2024
Net loss widened to $26.3M driven by increased R&D expenses
Cash and short-term investments reached $134M, supporting runway into 2027
Initiated first-in-human study for lead antibody program ABS-101
Absci
Absci
Absci Revenue by Segment
Revenue by Segment
Partner program Revenue
CapyFin.com Forward Guidance
Absci plans to advance multiple programs through preclinical and clinical development while maintaining financial flexibility with its current cash runway into 2027.
Positive Outlook
- Cash position supports operations into H1 2027
- Interim data readout for ABS-101 expected in H2 2025
- ABS-201 Phase 1 initiation targeted for early 2026
- NHP data supports clinical development of ABS-201
- Strong pipeline including internal and partnered programs
Challenges Ahead
- Continued net losses expected due to R&D investments
- No commercial products yet generating recurring revenue
- High reliance on future partnerships to sustain growth
- Limited revenue diversification at this stage
- Stock-based compensation contributing to rising costs